Gaurav Nayyar

Economics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice”.

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002267

N/A

0DataRank · unranked

41 citations

Gaurav Nayyar, Susiyan Jiang, Jeremy Rosenblum, Patrick Soon‐Shiong, Jeffrey T. Safrit +3 more

Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts

Molecular Therapy Oncology(2024)10.1016/j.omton.2024.200820

N/A

0DataRank · unranked

5 citations

Gaurav Nayyar, Meijuan Tian, Dean A. Lee, M. Fevzi Özkaynak, Jessica Ayala-Cuesta +11 more